Anal Cancer: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Anal cancer encompasses malignancies arising from the anal canal (between the anorectal junction and the anal verge) and the perianal skin. Approximately 10,000 new cases occur annually in the United States, with the global incidence approximately 2.5 per 100,000 and rising by 2-3% annually over recent decades, particularly among men who have sex with men (MSM) and HIV-positive individuals. Over 90% of anal cancers are squamous cell carcinomas (SCC) driven by human papillomavirus (HPV) — making anal cancer more closely related biologically to cervical cancer than to colorectal adenocarcinoma. The remaining minority includes adenocarcinoma (from anal glands or proximal anal canal), melanoma, and small cell carcinoma. Anal SCC represents 1-2% of all gastrointestinal malignancies. The AJCC 8th edition distinguishes T (tumor size and invasion), N (inguinal, mesorectal, and pelvic lymph nodes), and M (distant) staging. Critically, anal cancer differs from most solid tumors in that organ preservation with definitive chemoradiation (not surgery) is the standard approach — the Nigro protocol achieves sphincter preservation without permanent colostomy in over 80% of patients with localized disease. Five-year overall survival is approximately 82% for localized, 62% for regional, and 35% for distant metastatic disease per SEER data.

Human papillomavirus (HPV) infection is the central oncogenic driver — detected in more than 90% of anal SCCs, with HPV16 and HPV18 responsible for approximately 80-85% of anal cancers. HPV integration disrupts the E6/E7 oncoproteins, inactivating TP53 and RB tumor suppressor pathways and enabling uncontrolled proliferation of anal squamous epithelium. The oncogenic pathway closely parallels HPV-driven cervical cancer, progressing through anal intraepithelial neoplasia (AIN) grades 1-3 to invasive SCC over years. Key risk factors: HIV infection and immunosuppression (approximately 40-fold increased anal cancer risk, attributed to impaired HPV clearance and sustained viral replication); men who have sex with men (MSM) — highest-risk group with incidence approaching 137 per 100,000 HIV-positive MSM annually; history of cervical, vulvar, or vaginal HPV-related dysplasia or cancer (shared HPV exposure patterns); solid organ transplant recipients on immunosuppressive therapy (approximately 4-5-fold elevated risk); multiple sexual partners increasing cumulative HPV exposure probability; anal receptive intercourse; cigarette smoking (recognized independent co-carcinogen — approximately 2-fold elevated risk in active smokers via impairment of local immune surveillance); and HPV infection without immunosuppression (including the general population without established risk factors). Anal SCC is not related to colorectal adenocarcinoma — FAP and Lynch syndrome do not substantially increase anal SCC risk.

Symptoms of anal cancer are frequently non-specific and commonly misattributed to benign conditions — particularly hemorrhoids — causing median diagnostic delays of 6-12 months from symptom onset to diagnosis. Rectal bleeding is the cardinal presenting symptom, occurring in approximately 50% of patients — typically bright red blood per rectum, often noticed on toilet paper or in the toilet bowl. Anal pain or pressure: persistent, dull, or aching perianal discomfort that may worsen with defecation and does not respond to conservative hemorrhoid treatment. Pruritus ani: itching around the anal opening, sometimes the sole early symptom. Mucous discharge: clear or blood-stained mucous noted independently of defecation. A palpable anal or perianal mass or lump — may be painless initially, growing to become tender and ulcerated over time. Changes in bowel habit: urgency, tenesmus (sensation of incomplete evacuation), reduction in stool caliber, or frank diarrhea from locally advanced rectal involvement. Fecal incontinence from sphincter infiltration in advanced local disease. Perianal skin changes: erosion, induration, or a raised area around the anus that does not heal. Inguinal lymphadenopathy: enlarged, firm inguinal nodes — often the first sign of regional spread in perianal or distal anal canal tumors. Distant metastases (liver, lung, bone) may produce systemic symptoms including fatigue, weight loss, and organ-specific features in advanced disease.

Histological tissue diagnosis is established by anoscopy or proctoscopy with directed biopsy of suspicious anal lesions — multiple biopsies should be taken given multifocal HPV involvement. Digital rectal examination (DRE) assesses tumor extent, depth of invasion, sphincter involvement, and palpable perirectal or inguinal lymphadenopathy. Examination under anesthesia (EUA) is performed for accurate measurement of tumor dimensions in large or painful tumors. HIV testing and CD4 cell count are mandatory in all patients — HIV status guides immune risk stratification, ART management during chemoradiation, and eligibility for dose-modified versus standard treatment protocols. MRI pelvis (gadolinium-enhanced, high-resolution T2-weighted sequences): standard for local staging — T category assessment, sphincter infiltration, levator ani involvement, presacral space invasion, and mesorectal and inguinal lymph node characterization. PET-CT (18F-FDG): superior sensitivity for inguinal, pelvic, and distant nodal staging compared to CT alone — changes management in approximately 20% of patients; essential for radiation planning. AJCC 8th edition TNM staging: T1 (below 2 cm), T2 (2-5 cm), T3 (above 5 cm), T4 (adjacent organ invasion); N1 (inguinal, mesorectal, internal iliac nodes); M1 (distant metastasis). HPV genotyping (from tumor biopsy) confirms HPV-driven histology. p16 IHC as surrogate for HPV integration. Baseline CBC, comprehensive metabolic panel, and renal function (creatinine clearance for cisplatin eligibility in ACT II trial protocol).

Organ-preserving definitive chemoradiation is the standard curative approach for stage I-III anal SCC — achieving sphincter preservation in over 80% of patients without the need for permanent colostomy. Nigro protocol (standard first-line): concurrent 5-fluorouracil (1,000 mg/m2/day continuous infusion days 1-4 and 29-32) plus mitomycin C (10-15 mg/m2 bolus day 1 only) with external beam radiotherapy (45-54 Gy to the primary tumor and elective nodal volumes via IMRT — intensity-modulated radiotherapy preferred to reduce toxicity, including bone marrow sparing). IMRT reduces grade 3-4 hematological, GI, and genitourinary toxicities compared to 3D conformal RT. ACT II trial compared mitomycin C versus cisplatin and found mitomycin C superior — mitomycin C remains standard; capecitabine (825 mg/m2 orally twice daily during radiotherapy) is used as an alternative to continuous infusion 5-FU. Clinical response assessment at 8-26 weeks post-chemoradiation via DRE, anoscopy, and MRI pelvis — complete response is anticipated in approximately 75-85% of patients; partial or mixed response requires biopsy before surgical intervention, as delayed complete responses can occur up to 6 months. Abdominoperineal resection (APR): salvage surgery for biopsy-proven residual disease or local recurrence after definitive chemoradiation — achieves R0 resection in approximately 50-70% with permanent colostomy and 5-year salvage survival of approximately 30-50%. HIV-positive patients receive standard Nigro protocol with concurrent ART; dose reduction may be required for patients with CD4 below 200 cells/μL. Metastatic anal SCC: platinum-based chemotherapy (carboplatin plus paclitaxel or cisplatin plus 5-FU as first-line); nivolumab and pembrolizumab show durable responses in second-line (ORR approximately 20%) — FDA-approved for MSI-H or unselected anal SCC; retifanlimab plus carboplatin-paclitaxel demonstrated improved PFS in first-line metastatic disease (POD1UM-303 trial, 2024).

Anal squamous cell carcinoma carries a good prognosis for localized disease when treated with definitive chemoradiation. Five-year overall survival is approximately 82% for localized disease (T1-T2, N0), approximately 62% for regional disease with lymph node involvement, and approximately 35% for distant metastatic disease per SEER data. After the Nigro protocol chemoradiation, approximately 75-85% of patients achieve complete clinical response — assessed at 8-26 weeks post-treatment — with sphincter preservation in over 80%, avoiding a permanent colostomy. Tumor size (T stage) is the dominant prognostic factor: T1-T2 tumors have 5-year survival exceeding 80%, while T3-T4 tumors carry approximately 60-65% and 45-55% respectively. Lymph node involvement at diagnosis reduces 5-year survival by approximately 20-25 percentage points compared to node-negative disease. Local recurrence occurs in approximately 20-30% of patients, typically within the first 2-3 years; salvage abdominoperineal resection (APR) achieves R0 resection in approximately 50-70% of cases, with 5-year post-salvage survival of approximately 30-50%. HIV-positive patients who maintain CD4 above 200 cells/μL on ART achieve outcomes comparable to HIV-negative patients. Recovery timeline: most patients complete acute treatment in 5-6 weeks and recover from acute toxicities over 6-8 weeks; long-term late effects — including sexual dysfunction, bowel urgency and incontinence, skin changes, and secondary malignancy risk — require structured long-term surveillance. Regular pelvic MRI and clinical examination are recommended at 3-6 month intervals for the first 3 years after treatment completion.

HPV vaccination with the 9-valent vaccine (Gardasil 9) is the most effective primary prevention strategy and is recommended for all individuals aged 9-26 years (and up to age 45 in shared decision-making), ideally before sexual debut. HIV-positive individuals should be vaccinated regardless of age given their dramatically elevated anal cancer risk. Smoking cessation reduces anal SCC risk as tobacco is a co-carcinogen. High-risk individuals — MSM, HIV-positive persons, immunosuppressed patients, and women with prior HPV-related genital dysplasia — should undergo regular anal Pap cytology and, if abnormal, high-resolution anoscopy. Treating anal intraepithelial neoplasia (AIN) grade 2-3 before progression to invasive cancer is an effective secondary prevention strategy.

Any rectal bleeding that persists beyond 2-3 weeks, or any anal bleeding not clearly attributable to a previously diagnosed haemorrhoid, should be evaluated medically — anal cancer is frequently misdiagnosed as haemorrhoids, causing harmful delays. Persistent anal pain, itching, a lump at the anal margin, or mucous discharge of unknown cause warrant anoscopic examination. HIV-positive individuals and MSM with any anal symptoms should have a low threshold for evaluation given their very high relative risk. Women with a history of cervical, vulvar, or vaginal HPV-related dysplasia or cancer are at elevated anal cancer risk and benefit from regular examination. Any palpable inguinal lymphadenopathy in the context of anal symptoms should be evaluated promptly, as lymph node spread significantly impacts treatment planning.